News & press releases

PCMA: DIR Legislation Would Increase Premiums, Medicare Part D Costs

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on H.R. 1038, legislation introduced by Reps. Morgan Griffith (R-VA) and Peter Welch (D-VT), that would prohibit Medicare Part D plans from using direct and indirect remuneration (DIR) for pharmacies in Part D: “Medicare Part D is overwhelmingly popular with a 90%…

0 comments

PCMA Releases New Video: “What is Drug Price Transparency?”

(Washington, D.C.) — As part of its DrugBenefitSolutions.com campaign, the Pharmaceutical Care Management Association (PCMA) today released a new video, “What is drug price transparency?” explaining how transparency is widely used in the prescription drug marketplace for patients and employers, and highlighting that “the wrong kind” of transparency can “backfire” by reducing competition and resulting…

0 comments

PCMA Refutes Report from Oncologist Splinter Group on Medicare Part D

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on a new report by a splinter group of oncologists attacking the use of direct and indirect remuneration (DIR) in the popular Medicare Part D program: “Today’s attack on Medicare Part D plans’ tools to reduce drug costs is a thinly veiled…

0 comments

More

SmartBrief industry news

          More

          More great information…

          NBER Paper Shows Rx Copay Coupons Raise Costs

          Branded pharmaceutical manufacturers frequently offer “copay coupons” that insulate consumers from cost-sharing, thereby undermining insurers’ ability to influence drug utilization. We study the impact of copay coupons on branded drugs first facing generic entry between 2007 and 2010. Read more.

          0 comments

          New Research: Copay Coupons Significantly Increase Prescription Drug Costs

          A research team from Harvard, Northwestern and the University of California, Los Angeles, looked at brand-name drugs that also had…Read more.

          0 comments

          Magellan Rx Management: Medical Pharmacy Trend Report

          March 2015 Magellan Rx Management: 2015 Medical Pharmacy Trend Report  Magellan Rx Management is pleased to present the sixth edition of our Medical Pharmacy Trend Report,™ the only detailed source for current medical benefit drug management approaches and data benchmarking. Approximately 50 percent of the $124 billion annual specialty drug spend is billed on the medical benefit, yet visibility into this spend generally…

          0 comments